drugset / Trial / NCT01626976
A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects
RandomizedCrossoverDouble-blindBasic science
Summary
This is the first-in-human study for an oral investigational compound, PF-06282999, in order to assess its safety, tolerability and pharmacokinetics in humans across a wide range of dose levels.
Timeline
- Start
- 2012-06
- Primary completion
- 2013-03
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-06282999 | Small molecule | 20 mg | Oral |
| Subject | PF-06282999 | Small molecule | 125 mg | Oral |
| Subject | PF-06282999 | Small molecule | 200 mg | Oral |
| Subject | PF-06282999 | Small molecule | 500 mg | Oral |
| Subject | PF-06282999 | Small molecule | 1500 mg | Oral |
Indications
No indication recorded.